Study of INCA 0186 in Subjects With Advanced Solid Tumors

Active:	No
Cancer Type:	Colon/Rectal Cancer Liver Cancer / Hepatoblastoma Stomach/ Gastric Cancer	NCT ID:	NCT04989387
Trial Phases:	Phase I	Protocol IDs:	INCA 0186-101 (primary) NCI-2022-01925
Eligibility:	18 - 90 Years, Male and Female	Study Type:	Treatment
Study Sponsor:	Incyte Corporation
NCI Full Details:	http://clinicaltrials.gov/show/NCT04989387

Summary

This is an open-label, nonrandomized, multicenter, dose escalation, and dose expansion
first-in human (FIH) Phase 1 study to determine the safety, tolerability, PK,
pharmacodynamics, and preliminary efficacy of INCA00186 when given alone or in
combination with INCB106385 and/or retifanlimab in participants with specific advanced
solid tumors; squamous cell carcinoma of the head and neck (SCCHN) and specified
gastrointestinal (GI) malignancies have been selected as indications of interest for this
study. Participants with CD8 T-cell-positive tumors will be selected as these tumors are
more likely to respond to immunotherapy.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.